JP2008535819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535819A5 JP2008535819A5 JP2008503191A JP2008503191A JP2008535819A5 JP 2008535819 A5 JP2008535819 A5 JP 2008535819A5 JP 2008503191 A JP2008503191 A JP 2008503191A JP 2008503191 A JP2008503191 A JP 2008503191A JP 2008535819 A5 JP2008535819 A5 JP 2008535819A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- vegf trap
- protein
- sucrose
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66512505P | 2005-03-25 | 2005-03-25 | |
| US60/665,125 | 2005-03-25 | ||
| PCT/US2006/010600 WO2006104852A2 (en) | 2005-03-25 | 2006-03-22 | Vegf antagonist formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012282406A Division JP5752671B2 (ja) | 2005-03-25 | 2012-12-26 | Ｖｅｇｆアンタゴニスト製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008535819A JP2008535819A (ja) | 2008-09-04 |
| JP2008535819A5 true JP2008535819A5 (https=) | 2013-02-21 |
| JP5376573B2 JP5376573B2 (ja) | 2013-12-25 |
Family
ID=36678320
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503191A Expired - Lifetime JP5376573B2 (ja) | 2005-03-25 | 2006-03-22 | Ｖｅｇｆアンタゴニスト製剤 |
| JP2012282406A Expired - Lifetime JP5752671B2 (ja) | 2005-03-25 | 2012-12-26 | Ｖｅｇｆアンタゴニスト製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012282406A Expired - Lifetime JP5752671B2 (ja) | 2005-03-25 | 2012-12-26 | Ｖｅｇｆアンタゴニスト製剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (16) | US20060217311A1 (https=) |
| EP (3) | EP3195874A1 (https=) |
| JP (2) | JP5376573B2 (https=) |
| KR (1) | KR101327270B1 (https=) |
| CN (2) | CN102614134B (https=) |
| AU (1) | AU2006229930C1 (https=) |
| CA (3) | CA2598711C (https=) |
| CY (2) | CY1116980T1 (https=) |
| DK (2) | DK1861116T3 (https=) |
| ES (2) | ES2633574T3 (https=) |
| HU (2) | HUE034109T2 (https=) |
| IL (2) | IL185606A (https=) |
| LT (1) | LT2586459T (https=) |
| NZ (1) | NZ560713A (https=) |
| PL (2) | PL2586459T3 (https=) |
| PT (2) | PT2586459T (https=) |
| SI (2) | SI1861116T1 (https=) |
| WO (1) | WO2006104852A2 (https=) |
| ZA (1) | ZA200708845B (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7572893B2 (en) * | 2004-08-17 | 2009-08-11 | Regeneron Pharmaceuticals, Inc. | IL-1 antagonist formulations |
| US7655758B2 (en) | 2004-08-17 | 2010-02-02 | Regeneron Pharmaceuticals, Inc. | Stable liquid IL-1 antagonist formulations |
| CN102614134B (zh) | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
| US7608261B2 (en) * | 2006-06-16 | 2009-10-27 | Regeneron Pharmacuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| AU2012202859C1 (en) * | 2006-06-16 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| AU2008319053B2 (en) | 2007-11-01 | 2012-04-26 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
| EP3785735A1 (en) * | 2008-11-03 | 2021-03-03 | Molecular Partners AG | Binding proteins inhibiting the vegf-a receptor interaction |
| BR112013008366B1 (pt) | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| CN102552875B (zh) * | 2010-12-09 | 2015-05-20 | 上海国健生物技术研究院 | 一种双功能vegf受体融合蛋白制剂 |
| KR20260004598A (ko) | 2011-01-13 | 2026-01-08 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| CN103547255B (zh) * | 2011-04-14 | 2018-07-06 | 加利福尼亚大学董事会 | 多层薄膜药物递送装置以及其制造和使用方法 |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| PL3574897T3 (pl) | 2011-11-18 | 2022-05-09 | Regeneron Pharmaceuticals, Inc. | Postać użytkowa o przedłużonym uwalnianiu zawierająca mikrocząstki białka polimerowego do stosowania w ciele szklistym oka w leczeniu naczyniowych zaburzeń oczu |
| AU2013212587B2 (en) | 2012-01-23 | 2017-07-20 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-Ang2 antibodies |
| SG10201700360VA (en) * | 2012-03-16 | 2017-03-30 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
| AR092325A1 (es) * | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| WO2014006113A1 (en) | 2012-07-03 | 2014-01-09 | Sanofi | Method of treating cancer by effective amounts of aflibercept |
| UY34962A (es) * | 2012-08-02 | 2014-02-28 | Sanofi Sa | Articulo de fabricacion que comprende aflibercept o ziv-aflibercept. |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| CN103110105A (zh) * | 2012-11-14 | 2013-05-22 | 江苏江山制药有限公司 | 食品添加剂无糖维生素c钠盐颗粒的生产方法 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR102486321B1 (ko) | 2014-07-18 | 2023-01-09 | 사노피 | 암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법 |
| CN104940926B (zh) | 2014-09-25 | 2017-09-22 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| CN105435222B (zh) | 2014-09-25 | 2018-05-29 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| JP6781508B2 (ja) * | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| US10894083B2 (en) | 2015-01-28 | 2021-01-19 | Pfizer Inc. | Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation |
| KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| PT3384049T (pt) | 2015-12-03 | 2023-08-18 | Regeneron Pharma | Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| AU2017213103B2 (en) | 2016-01-26 | 2022-08-11 | Formycon Ag | Liquid formulation of a VEGF antagonist |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| CA3039655A1 (en) | 2016-10-07 | 2018-04-12 | Regeneron Pharmaceuticals, Inc. | Room temperature stable lyophilized protein |
| CN109937034B (zh) * | 2016-11-21 | 2022-09-16 | 济世-伊沃泰克生物制品有限公司 | 阿柏西普制剂及其用途 |
| USD849856S1 (en) | 2017-06-28 | 2019-05-28 | Jumpsport, Inc. | Standing platform |
| UA125971C2 (uk) * | 2017-07-25 | 2022-07-20 | Джянгсу Хенгруй Медісін Ко., Лтд. | Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| JP7536640B2 (ja) | 2017-11-17 | 2024-08-20 | アムジエン・インコーポレーテツド | ＶＥＧＦＲ－Ｆｃ融合タンパク質製剤 |
| CA3081094A1 (en) | 2017-11-20 | 2019-05-23 | Alison J. GILLESPIE | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| EP4122486A1 (en) | 2017-11-30 | 2023-01-25 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat diabetic retinopathy |
| KR102742284B1 (ko) * | 2017-12-22 | 2024-12-16 | 삼성바이오에피스 주식회사 | Vegf 길항제를 포함하는 액상 조성물 |
| FI3743091T3 (fi) | 2018-01-26 | 2025-01-03 | Univ California | Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| EP3761953A1 (en) | 2018-03-08 | 2021-01-13 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| US11103552B2 (en) * | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| WO2021050687A1 (en) | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021108255A1 (en) | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Long-acting vegf inhibitors for intraocular neovascularization |
| US11180540B2 (en) | 2019-12-06 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| KR102337471B1 (ko) * | 2019-12-23 | 2021-12-09 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질을 포함하는 약제학적 제형 |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| US20230312683A1 (en) * | 2020-07-31 | 2023-10-05 | Celltrion Inc. | Stable pharmaceutical preparation |
| CN120204358A (zh) * | 2023-12-27 | 2025-06-27 | 成都康弘生物科技有限公司 | 一种含有抗vegf的融合蛋白的药物组合物 |
| US12240888B1 (en) | 2024-04-29 | 2025-03-04 | QILU Pharmaceutical, Co., Ltd. | Composition comprising aflibercept and a variant thereof, and related methods and uses |
| TW202602913A (zh) | 2024-04-29 | 2026-01-16 | 大陸商齊魯製藥有限公司 | 包含阿柏西普和其變體的組合物以及相關方法和應用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
| WO1993022336A1 (en) * | 1992-04-30 | 1993-11-11 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor viii complex |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9410534D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
| CA2226575C (en) * | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JPH09154588A (ja) * | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Ｖｅｇｆ結合性ポリペプチド |
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| JPH10273450A (ja) | 1997-03-27 | 1998-10-13 | Toagosei Co Ltd | 眼内血管新生性疾患治療薬 |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JPH1180024A (ja) | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | 角膜血管新生阻害剤 |
| US6436897B2 (en) * | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| ES2265931T3 (es) | 1999-04-16 | 2007-03-01 | Genentech, Inc. | Variantes del factor de crecimiento celular endotelial vascular (vegf) y sus usos. |
| EP1179541B1 (en) | 1999-04-28 | 2004-06-16 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting VEGF |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7396664B2 (en) * | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CN100523187C (zh) | 1999-06-08 | 2009-08-05 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| US7001892B1 (en) * | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| CA2454587C (en) * | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| JP5290489B2 (ja) | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｉｇｇ抗体の安定な液体医薬製剤 |
| PT1946776T (pt) | 2002-02-27 | 2017-03-17 | Immunex Corp | Composição de tnfr-fc estabilizada compreendendo arginina |
| US7052691B2 (en) | 2003-03-28 | 2006-05-30 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking VEGF-mediated activity |
| CN1798575A (zh) * | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
| US20040266688A1 (en) | 2003-05-14 | 2004-12-30 | Nayak Nihar R | Methods for modulating endometrium |
| AU2004242586C1 (en) | 2003-05-28 | 2011-02-24 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using VEGF antagonists |
| EP1631317A2 (en) | 2003-06-06 | 2006-03-08 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitors for tumor regression |
| ITMI20031261A1 (it) | 2003-06-20 | 2004-12-21 | Messersi Packaging Srl | Macchina reggiatrice con gruppo perfezionato di movimentazione della reggia. |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| CA2534197A1 (en) | 2003-08-06 | 2005-02-24 | Thomas Jefferson University | Use of a vegf antagonist in combination with radiation therapy |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| WO2005087808A2 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Growth factor binding constructs materials and methods |
| WO2005102303A2 (en) | 2004-04-21 | 2005-11-03 | Advanced Ocular Systems Limited | Antiprostaglandins for the treatment of ocular pathologies |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| KR100897379B1 (ko) | 2004-06-08 | 2009-05-14 | 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 | 혈관신생-저해 키메릭 단백질 및 그 사용 |
| CN1304427C (zh) | 2004-06-08 | 2007-03-14 | 成都康弘生物科技有限公司 | 抑制血管新生的融合蛋白质及其用途 |
| EP1753442A2 (en) * | 2004-06-10 | 2007-02-21 | Regeneron Pharmaceuticals, Inc. | Method of administering and using vegf inhibitors for the treatment of human cancer |
| MXPA06014689A (es) | 2004-06-18 | 2008-03-11 | Regeneron Pharma | Inhibidores del vegf para el tratamiento de efusion pleural maligna. |
| US7378095B2 (en) | 2004-07-30 | 2008-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
| PL1802334T3 (pl) | 2004-10-21 | 2013-01-31 | Genentech Inc | Sposób leczenia wewnątrzgałkowych chorób neowaskularnych |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| CN102614134B (zh) | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
| MX2007015476A (es) | 2005-06-14 | 2008-02-25 | Amgen Inc | Formulaciones de proteina autoamortiguadoras. |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| CN100567325C (zh) | 2006-03-31 | 2009-12-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 |
| US7608261B2 (en) | 2006-06-16 | 2009-10-27 | Regeneron Pharmacuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| CN102233132B (zh) | 2010-04-28 | 2013-10-23 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用 |
| CN102380096B (zh) | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| CN107115294B (zh) | 2012-01-19 | 2019-10-18 | 北京康弘生物医药有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| DE202013000688U1 (de) | 2012-07-03 | 2013-03-05 | Novartis Ag | Glas-Spritze |
| JP6071099B1 (ja) | 2014-01-25 | 2017-02-01 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | 血管の新生又は成長を抑制する融合タンパク質及びその用途 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
-
2006
- 2006-03-22 CN CN201210090068.4A patent/CN102614134B/zh not_active Expired - Lifetime
- 2006-03-22 CA CA2598711A patent/CA2598711C/en not_active Expired - Lifetime
- 2006-03-22 EP EP17159239.7A patent/EP3195874A1/en not_active Ceased
- 2006-03-22 PL PL13152402T patent/PL2586459T3/pl unknown
- 2006-03-22 EP EP13152402.7A patent/EP2586459B1/en not_active Expired - Lifetime
- 2006-03-22 CA CA3142945A patent/CA3142945A1/en active Pending
- 2006-03-22 LT LTEP13152402.7T patent/LT2586459T/lt unknown
- 2006-03-22 ZA ZA200708845A patent/ZA200708845B/xx unknown
- 2006-03-22 US US11/387,256 patent/US20060217311A1/en not_active Abandoned
- 2006-03-22 SI SI200631996T patent/SI1861116T1/sl unknown
- 2006-03-22 HU HUE13152402A patent/HUE034109T2/en unknown
- 2006-03-22 DK DK06748594.6T patent/DK1861116T3/en active
- 2006-03-22 SI SI200632195T patent/SI2586459T1/sl unknown
- 2006-03-22 ES ES13152402.7T patent/ES2633574T3/es not_active Expired - Lifetime
- 2006-03-22 PT PT131524027T patent/PT2586459T/pt unknown
- 2006-03-22 PT PT67485946T patent/PT1861116E/pt unknown
- 2006-03-22 KR KR1020077024202A patent/KR101327270B1/ko not_active Expired - Lifetime
- 2006-03-22 EP EP06748594.6A patent/EP1861116B1/en not_active Expired - Lifetime
- 2006-03-22 NZ NZ560713A patent/NZ560713A/en not_active IP Right Cessation
- 2006-03-22 CA CA2995971A patent/CA2995971A1/en active Pending
- 2006-03-22 JP JP2008503191A patent/JP5376573B2/ja not_active Expired - Lifetime
- 2006-03-22 AU AU2006229930A patent/AU2006229930C1/en active Active
- 2006-03-22 HU HUE06748594A patent/HUE027096T2/en unknown
- 2006-03-22 CN CN2006800085696A patent/CN101141975B/zh not_active Expired - Lifetime
- 2006-03-22 DK DK13152402.7T patent/DK2586459T3/en active
- 2006-03-22 ES ES06748594.6T patent/ES2548238T3/es not_active Expired - Lifetime
- 2006-03-22 PL PL06748594T patent/PL1861116T3/pl unknown
- 2006-03-22 WO PCT/US2006/010600 patent/WO2006104852A2/en not_active Ceased
-
2007
- 2007-08-30 IL IL185606A patent/IL185606A/en active IP Right Grant
-
2010
- 2010-07-13 US US12/835,065 patent/US8110546B2/en not_active Expired - Lifetime
-
2012
- 2012-01-04 US US13/343,214 patent/US8404638B2/en not_active Expired - Lifetime
- 2012-03-23 US US13/428,510 patent/US8710004B2/en not_active Expired - Lifetime
- 2012-12-26 JP JP2012282406A patent/JP5752671B2/ja not_active Expired - Lifetime
-
2013
- 2013-06-04 US US13/909,745 patent/US8921316B2/en not_active Expired - Lifetime
- 2013-06-27 IL IL227215A patent/IL227215A/en active IP Right Grant
-
2014
- 2014-11-21 US US14/550,385 patent/US9416167B2/en not_active Expired - Lifetime
-
2015
- 2015-11-26 CY CY20151101068T patent/CY1116980T1/el unknown
-
2016
- 2016-03-08 US US15/064,343 patent/US9511140B2/en not_active Expired - Lifetime
- 2016-05-10 US US15/150,840 patent/US9636400B2/en not_active Expired - Fee Related
- 2016-11-03 US US15/342,989 patent/US20170073407A1/en not_active Abandoned
-
2017
- 2017-08-02 CY CY20171100827T patent/CY1119243T1/el unknown
- 2017-08-31 US US15/692,893 patent/US10406226B2/en not_active Expired - Lifetime
-
2019
- 2019-08-08 US US16/535,610 patent/US10857231B2/en not_active Expired - Lifetime
-
2020
- 2020-11-17 US US16/950,584 patent/US11806398B2/en active Active
-
2021
- 2021-05-04 US US17/307,240 patent/US20210252147A1/en not_active Abandoned
- 2021-05-05 US US17/308,801 patent/US20210252105A1/en not_active Abandoned
- 2021-05-06 US US17/313,627 patent/US20210393778A1/en not_active Abandoned
- 2021-05-07 US US17/314,992 patent/US20210393530A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535819A5 (https=) | ||
| JP6050902B2 (ja) | 即効型インスリン組成物 | |
| JP2016539921A5 (https=) | ||
| JP2009524595A5 (https=) | ||
| CY1124703T1 (el) | Μεθοδοι και συνθεσεις για παραδοση της ιδουρονικης-2-σουλφατασης στο κνς | |
| JP2018504420A5 (https=) | ||
| JP2015527402A5 (https=) | ||
| US20150157725A1 (en) | Transmucosal delivery of peptides and proteins | |
| PE20071063A1 (es) | Formulaciones de proteinas estables | |
| PH12021552788A1 (en) | Stabilized formulations containing anti-angptl3 antibodies | |
| KR20170061140A (ko) | 펩티드 또는 단백질 약물의 경구 전달을 위한 약제학적 제형 | |
| EA200700389A1 (ru) | Стабильный при хранении инфузионный раствор дигидроптеридинонов | |
| PE20120204A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| WO2009032246A3 (en) | Particulate compositions for delivery of poorly soluble drugs | |
| US9636376B2 (en) | Stable compositions of peptide epoxy ketones | |
| JP2019512012A5 (https=) | ||
| JP2019509311A5 (https=) | ||
| Sharma et al. | Permeation enhancers in the transmucosal delivery of macromolecules | |
| HRP20181021T1 (hr) | Formulacija za bispecifične aktivatore limfocita t (bites) | |
| JP2016515623A5 (https=) | ||
| Tratsiakovich et al. | Myocardial protection by co-administration of L-arginine and tetrahydrobiopterin during ischemia and reperfusion | |
| JP5892940B2 (ja) | クラウン化合物及び／又は対イオンと複合体化されたペプチドを含む粘膜送達組成物 | |
| JP2016534062A (ja) | 新規な安定製剤 | |
| JP2003504395A5 (https=) | ||
| TW201815410A (zh) | 藥物之經黏膜吸收促進劑 |